Rheumatoid arthritis (RA) is prevalent in ~1% of the population and is responsible for substantial financial and social burden. RA is a systemic disease, but the most obvious manifestations are in the joints. Current thera peutic best practice is to identify the disease at an early stage and treat it aggressively with a stepup regimen aimed at achieving com plete clinical remission. This strategy typically commences with methotrexate and, if needed, is followed up with addition of conventional synthetic or biologic therapeutic agents that target proinflammatory cytokines. Unfortunately, although the goal of remission is becoming more attainable, success is not proteins and metabolites) can vary according to cell type, are altered when cells activate, proliferate or differentiate and are perturbed by disease 3 . By being downstream at the con vergence of multiple pathways, smallmolecule metabolite profiling (known as metabolomics) of biofluids can provide signatures that might be able to discriminate between disease and health. Different tissues and immune cells might respond metabolically in unique ways to inflammatory mediators such as cytokines, and thereby biofluid metabolite profiles reflect these metabolic processes and might function as biomarkers of response to therapy.
Teitsma et al. 2 used clinical data that were originally derived from the 2year multi centre phase III doubleblind placebocontrolled UActEarly strategy trial (ClinicalTrials. gov identifier NCT01034137), which took 317 DMARDnaive patients with newly diag nosed RA, and randomized them to start treatment with tocilizumab (a humanized antiIL6 receptor monoclonal antibody), stepup methotrexate or a combination of the two drugs. Patients were treatedto target until sustained remission was achieved, defined as DAS28 <2.6 with ≤4 swollen joints for ≥24 weeks 4 . In this subgroup of 60 patients 2 , baseline serum metabolic profiles obtained on mass spectrometry platforms were used to vali date 'oxidative stress' , 'amines' and 'oxylip ins' in 37 patients with RA (median duration of symptoms 23 days, interquartile range 18-40), and achieving sustained drugfree remission (sDFR) was compared with serum profiles from 23 pati ents from the study who did not achieve sDFR (as a control).
Distinct baseline metabolic pathways iden tified in sera from patients achieving sDFR were highlighted across the three treatment arms, including histidine meta bolism in the tocilizumab and methotrexate arm, arachi donic acid metabolism in the tocilizumab arm and arginine and proline metabolism in the methotrexateonly arm 2 . Although only the top pathway in each of the treatment arms was high lighted, we note that the histidine meta bolism pathway in the methotrexate arm was also significant (P = 0.025 versus P = 0.022 for argi nine and proline). Interestingly, Kanarek et al. 5 previously emphasized the importance of histi dine metabolism in sensitivity to methotrexate in cancer, and the new data from Teitsma et al. . The search is on, there fore, not only to establish treatment regimens that can induce sustained clinical remission in patients with RA, but also to develop tech nologies to predict which therapeutic options will work in individual patients. A promis ing new study from Teitsma et al.
2 combines omics technologies to show that metabolite profiling of serum, when combined with transcriptomics and protein analysis, is able to stratify patient responses to methotrexate, tocilizumab or a combination of these drugs.
Cellular metabolism is required to sustain cells and tissues, but metabolic programmes (operating at the level of genes, gene transcripts, Previous publications from the UAct Early study have already included other packets of omics data 6, 7 . In one of these stud ies, highthroughput whole transcriptomic ribonucleic acid sequencing (RNAseq) from CD4 + T helper cells and CD14 + monocytes isolated at baseline from whole blood samples was used to identify differential gene expres sion networks from the same 60 patients 6 . That study showed that expression of differ ent clusters of genes was substantially altered for CD4 + T cells, depending on the subse quent treatment arm, with three pathways identified 6 . For example, in the tocilizumab and methotrexate arm, pathways related to transcription and translation were impor tant, whereas pathways related to migration of white blood cells and Gproteincoupled receptors were significant in the tocilizumab arm. In the methotrexate arm, pathways relat ing to response to a bacterial or biotic stim ulus were highlighted. No relevant networks could be identified in the sequenced CD14 + monocytes. This study 6 indicated that (at least in CD4 + T helper cells) differential expression of blood cell genes can be linked to drug effi cacy, but with the limitation that the focus was on the blood and was without analysis of synovium (the main site of inflammation in RA). In another publication from this study, proteomics data (obtained at baseline from serum) from the same 60 patients showed multiple proteins associated with achieving sDFR, but the addition of seven candidate protein biomarkers identified as clinical predictors did not enhance the prognosis of methotrexate treatment response 7 , suggesting that proteomics data alone are not sufficiently discriminatory and that further integration of data is required. Similarly, although IL6 signalling (the target of tocilizumab) has an important role in metabolism, the baseline level of IL6 in blood seems to be a weak pre dictor of the response to tocilizumab in RA, emphasizing that individual blood parameters can be less informative in isolation 8 . Previous work has suggested that baseline urine metabolic profiles can predict responses to biologic therapies, such as TNF inhibitors 9 . In this study, metabolites linked to degrada tion of amino acids were identified as predic tors of drug response. TNF is known to drive rheumatoid cachexia, in which muscle loss is substantial and so would drive protein degra dation leading to the appearance of amino acid byproducts in the urine. The presence of these byproducts would indicate the impor tance of TNF in driving disease in those patients and thus their responses to TNFtargeted therapy. Metabolic profiles in blood in very early arthritis are hetero geneous 10 , and might reflect whether the patient will develop chronic 2015-2023 (2013) .
